A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies
Identifieur interne : 000D27 ( Pmc/Curation ); précédent : 000D26; suivant : 000D28A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies
Auteurs : Milosz Faber ; Elaine W. Lamirande [États-Unis] ; Anjeanette Roberts [États-Unis] ; Amy B. Rice ; Hilary Koprowski ; Bernhard Dietzschold ; Matthias J. Schnell [États-Unis]Source :
- The Journal of general virology [ 0022-1317 ] ; 2005.
Abstract
Foreign viral proteins expressed by rabies virus (RV) have been shown to induce potent humoral and cellular immune responses in immunized animals. In addition, highly attenuated and, therefore, very safe RV-based vectors have been constructed. Here, an RV-based vaccine vehicle was utilized as a novel vaccine against severe acute respiratory syndrome coronavirus (SARS-CoV). For this approach, the SARS-CoV nucleocapsid protein (N) or envelope spike protein (S) genes were cloned between the RV glycoprotein G and polymerase L genes. Recombinant vectors expressing SARS-CoV N or S protein were recovered and their immunogenicity was studied in mice. A single inoculation with the RV-based vaccine expressing SARS-CoV S protein induced a strong SARS-CoV-neutralizing antibody response. The ability of the RV-SARS-CoV S vector to confer immunity after a single inoculation makes this live vaccine a promising candidate for eradication of SARS-CoV in animal reservoirs, thereby reducing the risk of transmitting the infection to humans.
Url:
DOI: 10.1099/vir.0.80844-0
PubMed: 15831955
PubMed Central: 1361274
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D27
Links to Exploration step
PMC:1361274Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies</title><author><name sortKey="Faber, Milosz" sort="Faber, Milosz" uniqKey="Faber M" first="Milosz" last="Faber">Milosz Faber</name><affiliation><nlm:aff wicri:cut=" and" id="A1"> Departments of Microbiology and Immunology</nlm:aff></affiliation></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W." last="Lamirande">Elaine W. Lamirande</name><affiliation wicri:level="1"><nlm:aff id="A2"> Laboratory of Infectious Diseases, NIAID, National Institutes of Health, MSC-8007, 50 South Drive, Bethesda, MD 20892-8007, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea> Laboratory of Infectious Diseases, NIAID, National Institutes of Health, MSC-8007, 50 South Drive, Bethesda, MD 20892-8007</wicri:regionArea></affiliation></author><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><affiliation wicri:level="1"><nlm:aff id="A2"> Laboratory of Infectious Diseases, NIAID, National Institutes of Health, MSC-8007, 50 South Drive, Bethesda, MD 20892-8007, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea> Laboratory of Infectious Diseases, NIAID, National Institutes of Health, MSC-8007, 50 South Drive, Bethesda, MD 20892-8007</wicri:regionArea></affiliation></author><author><name sortKey="Rice, Amy B" sort="Rice, Amy B" uniqKey="Rice A" first="Amy B." last="Rice">Amy B. Rice</name><affiliation><nlm:aff wicri:cut=" and" id="A1"> Departments of Microbiology and Immunology</nlm:aff></affiliation></author><author><name sortKey="Koprowski, Hilary" sort="Koprowski, Hilary" uniqKey="Koprowski H" first="Hilary" last="Koprowski">Hilary Koprowski</name><affiliation><nlm:aff wicri:cut=" and" id="A1"> Departments of Microbiology and Immunology</nlm:aff></affiliation></author><author><name sortKey="Dietzschold, Bernhard" sort="Dietzschold, Bernhard" uniqKey="Dietzschold B" first="Bernhard" last="Dietzschold">Bernhard Dietzschold</name><affiliation><nlm:aff wicri:cut=" and" id="A1"> Departments of Microbiology and Immunology</nlm:aff></affiliation></author><author><name sortKey="Schnell, Matthias J" sort="Schnell, Matthias J" uniqKey="Schnell M" first="Matthias J." last="Schnell">Matthias J. Schnell</name><affiliation wicri:level="1"><nlm:aff id="A3"> Biochemistry and Molecular Pharmacology, Thomas Jefferson University, 233 South 10th Street, Suite 350 BLSB, Philadelphia, PA 19107-5541, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea> Biochemistry and Molecular Pharmacology, Thomas Jefferson University, 233 South 10th Street, Suite 350 BLSB, Philadelphia, PA 19107-5541</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">15831955</idno><idno type="pmc">1361274</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1361274</idno><idno type="RBID">PMC:1361274</idno><idno type="doi">10.1099/vir.0.80844-0</idno><date when="2005">2005</date><idno type="wicri:Area/Pmc/Corpus">000D27</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000D27</idno><idno type="wicri:Area/Pmc/Curation">000D27</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000D27</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies</title><author><name sortKey="Faber, Milosz" sort="Faber, Milosz" uniqKey="Faber M" first="Milosz" last="Faber">Milosz Faber</name><affiliation><nlm:aff wicri:cut=" and" id="A1"> Departments of Microbiology and Immunology</nlm:aff></affiliation></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W." last="Lamirande">Elaine W. Lamirande</name><affiliation wicri:level="1"><nlm:aff id="A2"> Laboratory of Infectious Diseases, NIAID, National Institutes of Health, MSC-8007, 50 South Drive, Bethesda, MD 20892-8007, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea> Laboratory of Infectious Diseases, NIAID, National Institutes of Health, MSC-8007, 50 South Drive, Bethesda, MD 20892-8007</wicri:regionArea></affiliation></author><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><affiliation wicri:level="1"><nlm:aff id="A2"> Laboratory of Infectious Diseases, NIAID, National Institutes of Health, MSC-8007, 50 South Drive, Bethesda, MD 20892-8007, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea> Laboratory of Infectious Diseases, NIAID, National Institutes of Health, MSC-8007, 50 South Drive, Bethesda, MD 20892-8007</wicri:regionArea></affiliation></author><author><name sortKey="Rice, Amy B" sort="Rice, Amy B" uniqKey="Rice A" first="Amy B." last="Rice">Amy B. Rice</name><affiliation><nlm:aff wicri:cut=" and" id="A1"> Departments of Microbiology and Immunology</nlm:aff></affiliation></author><author><name sortKey="Koprowski, Hilary" sort="Koprowski, Hilary" uniqKey="Koprowski H" first="Hilary" last="Koprowski">Hilary Koprowski</name><affiliation><nlm:aff wicri:cut=" and" id="A1"> Departments of Microbiology and Immunology</nlm:aff></affiliation></author><author><name sortKey="Dietzschold, Bernhard" sort="Dietzschold, Bernhard" uniqKey="Dietzschold B" first="Bernhard" last="Dietzschold">Bernhard Dietzschold</name><affiliation><nlm:aff wicri:cut=" and" id="A1"> Departments of Microbiology and Immunology</nlm:aff></affiliation></author><author><name sortKey="Schnell, Matthias J" sort="Schnell, Matthias J" uniqKey="Schnell M" first="Matthias J." last="Schnell">Matthias J. Schnell</name><affiliation wicri:level="1"><nlm:aff id="A3"> Biochemistry and Molecular Pharmacology, Thomas Jefferson University, 233 South 10th Street, Suite 350 BLSB, Philadelphia, PA 19107-5541, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea> Biochemistry and Molecular Pharmacology, Thomas Jefferson University, 233 South 10th Street, Suite 350 BLSB, Philadelphia, PA 19107-5541</wicri:regionArea></affiliation></author></analytic><series><title level="j">The Journal of general virology</title><idno type="ISSN">0022-1317</idno><idno type="eISSN">1465-2099</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">Foreign viral proteins expressed by rabies virus (RV) have been shown to induce potent humoral and cellular immune responses in immunized animals. In addition, highly attenuated and, therefore, very safe RV-based vectors have been constructed. Here, an RV-based vaccine vehicle was utilized as a novel vaccine against severe acute respiratory syndrome coronavirus (SARS-CoV). For this approach, the SARS-CoV nucleocapsid protein (N) or envelope spike protein (S) genes were cloned between the RV glycoprotein G and polymerase L genes. Recombinant vectors expressing SARS-CoV N or S protein were recovered and their immunogenicity was studied in mice. A single inoculation with the RV-based vaccine expressing SARS-CoV S protein induced a strong SARS-CoV-neutralizing antibody response. The ability of the RV-SARS-CoV S vector to confer immunity after a single inoculation makes this live vaccine a promising candidate for eradication of SARS-CoV in animal reservoirs, thereby reducing the risk of transmitting the infection to humans.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">0077340</journal-id><journal-id journal-id-type="pubmed-jr-id">4747</journal-id><journal-id journal-id-type="nlm-ta">J Gen Virol</journal-id><journal-title>The Journal of general virology</journal-title><issn pub-type="ppub">0022-1317</issn><issn pub-type="epub">1465-2099</issn></journal-meta><article-meta><article-id pub-id-type="pmid">15831955</article-id><article-id pub-id-type="pmc">1361274</article-id><article-id pub-id-type="doi">10.1099/vir.0.80844-0</article-id><article-id pub-id-type="manuscript">NIHMS7221</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Faber</surname><given-names>Milosz</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Lamirande</surname><given-names>Elaine W.</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>Anjeanette</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Rice</surname><given-names>Amy B.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Koprowski</surname><given-names>Hilary</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Dietzschold</surname><given-names>Bernhard</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Schnell</surname><given-names>Matthias J.</given-names></name><xref rid="A3" ref-type="aff">3</xref><xref rid="FN1" ref-type="author-notes"></xref></contrib><aff id="A1"><label>1</label> Departments of Microbiology and Immunology and</aff><aff id="A3"><label>3</label> Biochemistry and Molecular Pharmacology, Thomas Jefferson University, 233 South 10th Street, Suite 350 BLSB, Philadelphia, PA 19107-5541, USA</aff><aff id="A2"><label>2</label> Laboratory of Infectious Diseases, NIAID, National Institutes of Health, MSC-8007, 50 South Drive, Bethesda, MD 20892-8007, USA</aff></contrib-group><author-notes><corresp id="FN1">Correspondence Matthias J. Schnell,<email>matthias.schnell@jefferson.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>23</day><month>12</month><year>2005</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2005</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>2</month><year>2006</year></pub-date><volume>86</volume><issue>Pt 5</issue><fpage>1435</fpage><lpage>1440</lpage><abstract><p id="P1">Foreign viral proteins expressed by rabies virus (RV) have been shown to induce potent humoral and cellular immune responses in immunized animals. In addition, highly attenuated and, therefore, very safe RV-based vectors have been constructed. Here, an RV-based vaccine vehicle was utilized as a novel vaccine against severe acute respiratory syndrome coronavirus (SARS-CoV). For this approach, the SARS-CoV nucleocapsid protein (N) or envelope spike protein (S) genes were cloned between the RV glycoprotein G and polymerase L genes. Recombinant vectors expressing SARS-CoV N or S protein were recovered and their immunogenicity was studied in mice. A single inoculation with the RV-based vaccine expressing SARS-CoV S protein induced a strong SARS-CoV-neutralizing antibody response. The ability of the RV-SARS-CoV S vector to confer immunity after a single inoculation makes this live vaccine a promising candidate for eradication of SARS-CoV in animal reservoirs, thereby reducing the risk of transmitting the infection to humans.</p></abstract><contract-num rid="AI1">R21 AI062964-01</contract-num><contract-sponsor id="AI1">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</contract-sponsor></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000D27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:1361274
|texte= A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:15831955" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |